Write a letter to your members of Congress. Download our easy-to-use template. Learn more >>>
The new drug Stelara (generic: ustekinumab) was approved by the US Food & Drug Administration for the treatment of moderate to severe psoriasis in adults on September 25, 2009. Read more >>>
The research pipeline identifies drugs currently being tested for psoriasis and/or psoriatic arthritis. The information in this pipeline chart comes from public sources and is as comprehensive as we understand it at the time of update.
The pipeline includes drugs that are in progress through phase II and phase III of clinical trials. The pipeline lists the name of the drug, the drug company, how it is administered, its mechanism of action (or how it works), the phase of study, and the indication (psoriasis or psoriatic arthritis).
Sometimes drugs have two names—the name that is used in the trial and then the brand name for when it is approved. Often the name in the trial is a combination of letters and numbers to indicate the compound's name during development at the drug company.
TOPICALS are applied to the skin, available either as prescription or over the counter. They are most commonly used to treat mild psoriasis.
INJECTABLES are either subcutaneous, given just under the skin, or intravenous, given into the vein. Both are most commonly used to treat moderate to severe psoriasis.
Privacy PolicyTerms of Use Copyright ©2009 National Psoriasis Foundation/USA